Generic Name:
dupilumab
Project Status:
Complete
Therapeutic Area:
Asthma
Manufacturer:
Sanofi Genzyme, a division of sanofi-aventis Canada Inc.
Brand Name:
Dupixent
Project Line:
Reimbursement Review
Project Number:
SR0667-000
NOC Status at Filing:
Post NOC
Details
Manufacturer Requested Reimbursement Criteria1:
Add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid dependent asthma with the following characteristics: 2 or more clinically significant asthma exacerbations in the last 12 months AND Blood eosinophils 150/mcL; OR FeNO 25 ppb; OR Treatment with maintenance oral corticosteroids; OR Clinically allergen-driven asthma
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
Dupixent is indicated as an add-on maintenance treatment in patients aged 12 years and older with severe asthma with a type 2/eosinophilic phenotype or oral corticosteroid-dependent asthma.
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.